Catalyst Event
Regeneron Pharmaceuticals Inc (REGN) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/24/2026, 12:00:00 AM
On March 24, 2026, Japan's MHLW approved Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP). This approval's impact is estimated.
Korean Translation
2026년 3월 24일, 일본 후생노동성(MHLW)은 중등도에서 중증의 수포성 유사천포창(BP) 성인 환자 치료를 위해 듀피젠트를 승인함. 일본 시장 내 최초의 표적 치료제 승인으로 중간 정도의 영향(5-10%)을 미칠 것으로 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM